Therefore, we propose a new clinical framework defined by the network that a lncRNA-GAS5 functioning as an inhibitor of E2F1 may inhibit cancer progression through the establishment of miR-34c and can induce cell cycle arrest and apoptosis at the G1/S checkpoint. This evidence concerns the gene E2F1 and cancer.